Zenas BioPharma (ZBIO) Cash & Equivalents (2023 - 2026)

Zenas BioPharma's Cash & Equivalents history runs 4 years deep, the most recent figure standing at $500.2 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 154.5% year-over-year to $500.2 million; the TTM figure through Mar 2026 stood at $500.2 million (up 154.5% YoY), while the FY2025 annual figure was $110.6 million, down 65.4% from the prior year.
• Cash & Equivalents was $500.2 million for Q1 2026 at Zenas BioPharma, up from $110.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $500.2 million in Q1 2026 to a low of $37.2 million in Q1 2024.
• Historically, Cash & Equivalents has averaged $181.5 million across 4 years, with a median of $115.6 million in 2025.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents soared 462.36% in 2024, then plunged 76.07% in 2025.
• A 4-year view of Cash & Equivalents shows it stood at $56.9 million in 2023, then jumped by 462.36% to $319.7 million in 2024, then sank by 65.4% to $110.6 million in 2025, then surged by 352.11% to $500.2 million in 2026.
• The last three Cash & Equivalents figures came in at $500.2 million (Q1 2026), $110.6 million (Q4 2025), and $115.6 million (Q3 2025), per Business Quant data.